Search

Search Constraints

You searched for: Author/Creator Itobayashi, Ei

Search Results

1. A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin–bilirubin grade. Issue 3 (2nd August 2017)

2. Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. (22nd July 2021)

3. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. (14th December 2022)

4. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Issue 2 (5th January 2021)

5. Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Issue 5 (9th February 2022)

6. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. Issue 2 (11th June 2021)

7. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (February 2023)

8. Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma. Issue 12 (3rd September 2022)

9. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Issue 7 (5th May 2021)

10. Characteristics and prognosis of hepatocellular carcinoma detected in patients with chronic hepatitis C after the eradication of hepatitis C virus: A multicenter study from Japan. Issue 8 (19th November 2015)